NASH Boston - 750x250 Brochure Download  (2)


2020-06-29 : FDA rejects Intercept Pharma’s drug for NASH

2020-06-26 : DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH

2020-06-24 : Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH

2020-06-15 : Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)

2020-05-11 : GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis

2020-05-07 : HighTide Therapeutics Announces Positive Topline Results From Phase 2a Study of HTD1801 in NASH Patients

2020-05-06 : Novo Nordisk's diabetes med semaglutide shows promise in NASH. Can it deliver in phase 3?

2020-04-16 : A new definition for metabolic associated fatty liver disease: an international expert consensus statement

2020-04-08 : GENFIT Reports Full-Year 2019 Financial Results and Corporate Update

2020-03-12 : CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update

2020-02-24 : NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo

2020-02-21 : GENFIT: Unblinding of Phase 3 RESOLVE-IT Data Deferred

2020-02-13 : Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

2020-01-29 : Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH

2020-01-28 : Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement

2020-01-28 : Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study

2020-01-25 : A 3 week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death

2020-01-21 : Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes

2019-12-18 : Boehringer Ingelheim discontinues development of BI 1467335 for NASH

2019-12-16 : Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

2019-12-05 : Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

2019-12-05 : Zydus Cadila files for Indian approval of saroglitazar for the treatment of NASH

2019-11-26 : GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH

2019-11-25 : CymaBay Therapeutics Halts Clinical Development of Seladelpar

2019-11-25 : FDA Accepts Intercept’s NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review

2019-11-12 : SGLT1/2 Inhibitor in NASH Improved Liver Biomarkers Evidence of weight loss may make licogliflozin a promising treatment option

2019-11-11 : Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

2019-11-08 : Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting

2019-10-30 : PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019


2019-10-28 : Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development


2019-10-17 : Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases

2019-10-07 : NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

2019-09-26 : Inventiva receives FDA Fast Track designation for lead asset lanifibranor in NASH

2019-09-25 : Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

2019-09-24 : PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH

2019-07-02 : Yuhan Corp. licenses out NASH pipeline to Boehringer Ingelheim for $870m

2019-06-25 : GENFIT and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China

2019-06-24 : Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis




2019-06-06 : Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry

2019-06-05 : GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL

2019-05-14 : GENFIT: Positive 36-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH

2019-04-25 : Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)

2019-04-18 : GENFIT announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC

2019-04-12 : Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

2019-04-02 : Novartis buys NASH biotech IFM Tre in potential $1.575 bn deal


2019-03-28 : Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis a

2019-03-21 : Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis

2019-03-20 : Novo Nordisk submits diabetes pill for U.S. approval

2019-03-20 : Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH

2019-03-20 : Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022

2019-03-18 : Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis

2019-03-14 : GENFIT announces Launch of Proposed Global Offering and Nasdaq listing

2019-03-11 : GENFIT announces FDA Protocol Clearance for Phase 2 Clinical Trial of Elafibranor in Pediatric NASH

2019-02-27 : GENFIT: Publication of the 2018 Registration Document IPO NASDAQ

2019-02-19 : Intercept Announces Positive Topline Results from Pivotal Phase 3 REGENERATE Study of Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

2019-02-15 : CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis

2019-02-11 : Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

2019-01-17 : Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results

2019-01-08 : Yuhan Corp. Signs US$785 Mil. Technology Export Contract with Gilead

2019-01-07 : Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference

2019-01-07 : Intercept Announces NASH and PBC Program Updates

2019-01-03 : GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic SteatoHepatitis (NASH)

2019-01-03 : Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

2018-12-20 : Results of the Phase I study of repeated and increasing doses to assess CER-209 in NASH/NAFLD

2018-12-17 : GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH

2018-12-06 : GENFIT: Positive Phase 2 Results from Study of Elafibranor in Primary Biliary Cholangitis

2018-12-05 : Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

2018-12-05 : Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

2018-12-04 : Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry DRAFT GUIDANCE

2018-12-03 : GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis

2018-12-03 : GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis

2018-11-27 : HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Nonalcoholic Steatohepatitis (NASH)


2018-11-13 : Phase 2 Data for Galmed Pharmaceutical's Aramchol™ in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018

2018-11-06 : ENYO Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV

2018-10-23 : The effects of metabolic status on non alcoholic fatty liver disease related outcomes, beyond the presence of obesity

2018-09-18 : Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol

2018-07-31 : Shire’s fast-track NASH drug abruptly stopped in phase 2

2018-06-11 : A critical review of endpoints for non-cirrhotic NASH therapeutic trials

2018-05-31 : Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial

2018-05-02 : Cirius Therapeutics Reaches Enrollment Target in Phase 2b EMMINENCE Trial in NASH

2018-04-18 : Novartis expands development programs for NASH through clinical collaboration with Allergan

2018-04-11 : GENFIT: Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort

2018-04-05 : Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial

2018-04-04 : Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality

2018-04-03 : MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis

2018-04-03 : Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis

2018-03-22 : A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease

2018-03-22 : High Consumption of Red and Processed Meats May Lead to Non-alcoholic Liver Disease

2018-03-21 : Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients

2018-03-19 : Aortic carboxypeptidase–like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis

2018-03-19 : Diabetes medicine reduces liver fat in nonalcoholic fatty liver disease

2018-03-09 : A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis

2018-03-08 : Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis

2018-03-07 : Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux

2018-03-07 : Immuron Reports Positive Results in NASH Clinical Trial

2018-02-28 : Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson

2018-02-27 : Poxel Presents Preclinical Proof-of-Concept Data for PXL770 in Non-Alcoholic Steatohepatitis (NASH) at Global NASH Congress 2018

2018-02-27 : NASH rapidly overtaking hepatitis C as cause of liver cancer

2018-02-21 : Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis

2018-02-18 : The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease

2018-02-01 : Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)

2018-02-01 : FDA adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease

2018-01-26 : Obeticholic Acid Monotherapy Leads to Jaundice in PBC Patient

2018-01-23 : GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA

2018-01-17 : Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease

2018-01-04 : 4 to 6 january 2018 the NASH TAG Conference in UTAH

2018-01-04 : Spitfire Pharma's SP-1373 outscored semaglutide and elafibranor in a biopsy-proven translational mouse model of non-alcoholic steatohepatitis (NASH)

2017-12-22 : Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum

2017-12-21 : Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program

2017-12-20 : Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study

2017-12-06 : Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial

2017-12-04 : Targeting bile acids and lipotoxicity for NASH treatment

2017-11-23 : Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis

2017-11-18 : Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients

2017-11-17 : PNPLA3 variant and portal/ periportal histological pattern in patients with biopsy-proven non- alcoholic fatty liver disease: a possible role for oxidative stress

2017-11-17 : Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization

2017-11-17 : Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance

2017-11-12 : Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease

2017-11-11 : Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

2017-11-06 : Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression

2017-11-06 : Obesity correlates with discordance in noninvasive tests for fibrosis

2017-11-03 : Article | OPEN Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors

2017-11-02 : Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)

2017-10-24 : Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH)

2017-10-24 : Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

2017-10-24 : VKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both Compounds...vs ELAFIBRANOR

2017-10-17 : An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease

2017-10-11 : Relburn-Metabolomics to Present Developments in Lead Programs for NASH and Gout

2017-10-06 : Relburn-Metabolomics Appoints Renowned Experts in Nonalcoholic Steatohepatitis (NASH) to its Scientific Advisory Board

2017-10-05 : Galmed Pharmaceuticals Announces Publication of Data on Aramchol™ Mechanism of Action in Hepatology Communications. Data Will Also Be Presented at AASLD

2017-10-01 : Comparative metabolic and hepatic effects of liraglutide, elafibranor and obeticholic acid in diet- induced and genetically obese mouse models of biopsy-confirmed NASH

2017-09-26 : Intercept Pharmaceuticals Inc said OCALIVA could carry a BOXED WARNING ! but no restrictions

2017-09-25 : Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients

2017-09-22 : New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial


2017-09-20 : FDA Issues Warning on Liver Injury from Intercept Pharma's (ICPT) Ocaliva

2017-09-18 : Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)

2017-09-12 : IMPORTANT PRESCRIBING INFORMATION SUBJECT: Liver injury, liver decompensation, liver failure, and death have been reported in primary biliary cholangitis (PBC) patients with moderate or severe hepatic impairment (Child-Pugh B and C) when OCALIVA® was dosed more frequently than recommended

2017-09-11 : Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)

2017-09-06 : Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH

2017-09-05 : Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B

2017-09-04 : Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis

2017-08-28 : Study Offers New Targets for Drugs Against Fatty Liver Disease and Liver Cancer

2017-08-22 : Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis


2017-08-16 : NASH Summit Europe 10-12 October, 2017 Frankfurt, Germany is Europe’s definitive forum which exists to solve the challenges drug developers face from discovery to late stage clinical development.

2017-08-14 : Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

2017-08-01 : Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH

2017-06-23 : GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH

2017-06-20 : Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models

2017-06-12 : Regulus hit as AstraZeneca hands back rights to one drug, R&D revamp culls two more

2017-06-08 : Positive results from the CER-209 Phase I Single Dose Tolerance study for NAFLD and NASH

2017-06-05 : Non-alcoholic steatohepatitis (NASH); metabolic syndrome Patient sample, mouse and non-human primate (NHP) studies suggest that enhancing TMBIM1 expression could help treat non-alcoholic steatohepatitis (NASH) and metabolic syndrome

2017-06-02 : New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017

2017-06-01 : GENFIT: Positive Outcome from the 1-year Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor

2017-06-01 : On May26, 2017, the Data and Safety Monitoring Committee (the DSMC) for clinical studies of Madrigal Pharmaceuticals,Inc.'s (the Company) MGL-3196, for the treatment of non-alcoholic steatohepatitis, held a pre-scheduled meeting to review data from the Company's Phase 2 clinical NASH trial.

2017-05-11 : Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)

2017-05-03 : Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH

2017-04-24 : GENFIT : the recruitment of the 1000 first patients of RESOLV'IT will be delayed to T1 2018

2017-04-23 : NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

2017-04-21 : Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017

2017-04-20 : Cerenis Therapeutics Announces the Initiation of the Phase 1 Clinical Study with CER-209 in NAFLD and NASH

2017-04-19 : Novartis joins forces with Allergan, pushing a NASH combo into late-stage development

2017-03-29 : Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis

2017-03-28 : GENFIT to host a series of KOL Meetings in NASH


2017-02-28 : Cempra\'s solithromycin fails to match standard of care in GC study, development in NASH suspended

2017-02-17 : CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

2017-02-10 : The 10 of february, 2017 INTERCEPT Announced a modification of the protocole and endpoints, theu say it was done with the endorsement of the FDA and will increase their chance of success, ate this time we do not know the changes in detail . if the reversion definition vas modified to fulfill with the one used by GENFIT , it id definitively not a good news for OCALIVA, they never reached it in the previous studies.

2017-02-06 : Immuron enrols first patient in paediatric fatty liver trial in the U.S.

2017-02-02 : Inventiva launches its initial public offering on the regulated market of Euronext Paris

2017-01-24 : TOBIRA-ALLERGAN- launch STELLARIS: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

2017-01-09 : Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017

2017-01-09 : Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study

2017-01-09 : Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical StudyCompany Plans to Launch a Clinical Development Program in NAFLDNASH in 2017 based on Gemcabene’s Lipid-Lowering and Inflammation Mechanism of Action

2017-01-05 : Phenex Pharmaceuticals AG Receives $100M Milestone Payment From Gilead (GILD)

2017-01-03 : Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

2016-12-19 : Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan

2016-12-16 : Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

2016-12-07 : NASH DeMili Test is online (

2016-11-14 : Genfit initiates paediatric NAFLD/NASH program in Europe

2016-11-14 : Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016

2016-11-02 : Gilead stated that no further development of simtuzumab will be pursued

2016-09-27 : GENFIT is Filing for IND Submission for New Indication of Elafibranor in Primary Biliary Cholangitis (PBC)


2016-09-20 : GENFIT: Significant Milestones Achieved under a New Qualification Program of Proprietary miRNAs and Algorithms for a Non-invasive NASH Diagnostic

2016-09-20 : Allergan buy TOBIRA for 1.7 billion $

2016-08-22 : Avolynt, Inc. Announces FDA Acceptance of IND to Commence Pivotal Trial of Remogliflozin for NASH

2016-08-20 : The NAFLD induced cost in 5 country (USA,UK,Italy,Germany, France) is close to 140 Billon $

2016-08-02 : Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis

2016-07-29 : Shire receives FDA Fast Track for Volixibat on NASH with fibrosis

2016-07-14 : Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year

2016-04-21 : The full publication of GENFIT GOLDEN results are Published in Gastroenterology

2016-04-21 : A very good overview on NASH and PBC trials by Mary E. Rinella

2016-04-12 : Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc

2016-04-04 : GILEAD Announces Aquisition of Nimbus Therapeutic -Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases -

2016-03-30 : Aramchol™ Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease

2016-01-15 : Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

2015-10-29 : OCA fails to meet primary endpoint in Japanese patients with NASH

2014-08-24 : Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A)

2014-01-29 : Preclinical data support anti-cancer effects of GFT505

0202-03-05 : Zydus announces world’s first drug for the treatment of Non-Cirrhotic NASH

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE